Analysts warn that these tariffs could lead to higher production costs, reduced profitability, and even drug shortages. As Trump’s tariff threats loom, investors are left questioning whether to hold ...

Amgen (NASDAQ:AMGN – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy ...

Quantbot Technologies LP boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 219.5% during the fourth ...

Those problems mean that so far only one T-cell engager has reached the market – Amgen’s Blincyto (blinatumomab) for leukaemia – although many others are coming through development.

Meanwhile, Amgen's bispecific antibody Blincyto (blinatumomab) also targets CD19 but is indicated for acute lymphoblastic leukaemia (ALL). CAR-Ts can be highly effective but are made by harvesting ...

Blinatumomab (Blincyto, Amgen) is indicated for 'the treatment of adult patients with Philadelphia chromosome negative CD19-positive B-cell precursor leukaemia ALL in the consolidation phase'. The ...